These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32650008)

  • 1. Pleiotropic effects of anti-diabetic drugs: A comprehensive review.
    Nath M; Bhattacharjee K; Choudhury Y
    Eur J Pharmacol; 2020 Oct; 884():173349. PubMed ID: 32650008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise.
    Kong M; Xie K; Lv M; Li J; Yao J; Yan K; Wu X; Xu Y; Ye D
    Biomed Pharmacother; 2021 Jan; 133():110975. PubMed ID: 33212375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of platelet-derived growth factor in type II diabetes mellitus and its complications.
    Shen S; Wang F; Fernandez A; Hu W
    Diab Vasc Dis Res; 2020; 17(7):1479164120942119. PubMed ID: 32744067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.
    Correia S; Carvalho C; Santos MS; Seiça R; Oliveira CR; Moreira PI
    Mini Rev Med Chem; 2008 Nov; 8(13):1343-54. PubMed ID: 18991752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes.
    Yaribeygi H; Atkin SL; Pirro M; Sahebkar A
    J Cell Physiol; 2019 Jun; 234(6):8286-8294. PubMed ID: 30417367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.
    Hsiao PJ; Wu KL; Chiu SH; Chan JS; Lin YF; Wu CZ; Wu CC; Kao S; Fang TC; Lin SH; Chen JS
    Clin Exp Nephrol; 2017 Aug; 21(4):694-704. PubMed ID: 27599981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights.
    Sarkar A; Fanous KI; Marei I; Ding H; Ladjimi M; MacDonald R; Hollenberg MD; Anderson TJ; Hill MA; Triggle CR
    Vasc Health Risk Manag; 2024; 20():255-288. PubMed ID: 38919471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Possible Role of Flavonoids in the Prevention of Diabetic Complications.
    Testa R; Bonfigli AR; Genovese S; De Nigris V; Ceriello A
    Nutrients; 2016 May; 8(5):. PubMed ID: 27213445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The safety of anti-diabetic drugs in heart failure].
    Frigy A; Germán-Salló M; Máthé L; Szabó M
    Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.
    Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Heerspink HJ; van Raalte DH
    Lancet Diabetes Endocrinol; 2015 May; 3(5):367-81. PubMed ID: 25943756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
    Kumawat VS; Kaur G
    Eur J Pharmacol; 2019 Nov; 862():172628. PubMed ID: 31461639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hypoglycemic anti-deafness capsules in diabetic patients with deafness and toxicological assessment in rats.
    Li R; Li M; Guo K; Li B; Hou J; Wu L; Liu X
    J Tradit Chin Med; 2013 Oct; 33(5):651-7. PubMed ID: 24660591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glifozines and cardiorenal outcomes.
    Di Lullo L; Bellasi A; Guastamacchia E; Triggiani V; Ronco C; Lavalle C; Di Iorio BR; Russo D; Cianciolo G; La Manna G; Settembrini S
    Minerva Cardioangiol; 2020 Jun; 68(3):188-196. PubMed ID: 32083429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
    Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis and risk of fracture in patients with diabetes: an update.
    Montagnani A; Gonnelli S; Alessandri M; Nuti R
    Aging Clin Exp Res; 2011 Apr; 23(2):84-90. PubMed ID: 21743287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.